Loading…

Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer

We sought to investigate the association between visceral obesity with disease recurrence and survival in early-stage colorectal cancer (CRC) patients. We also wanted to examine if such an association, if exists, is influenced by metformin use. Stage I/II CRC adenocarcinoma patients treated surgical...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-05, Vol.13 (1), p.8401-8401, Article 8401
Main Authors: Vedire, Yeshwanth Reddy, Mukherjee, Sarbajit, Dondapati, Sumedha, Yendamuri, Sai
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We sought to investigate the association between visceral obesity with disease recurrence and survival in early-stage colorectal cancer (CRC) patients. We also wanted to examine if such an association, if exists, is influenced by metformin use. Stage I/II CRC adenocarcinoma patients treated surgically were identified. L3 level CT VFI (visceral fat index) was used as a metric of visceral obesity and was calculated as the proportion of total fat area composed of visceral fat. N = 492. 53% were males, 90% were Caucasians, 35% had stage I disease, and 14% used metformin. 20.3% patients developed a recurrence over a median follow-up of 56 months. VFI was associated with both RFS and OS in a multivariate model, but not BMI. The final multivariate model for RFS included an interaction term for VFI and metformin ( p  = 0.04). Confirming this result, subgroup analysis showed an increasing VFI was associated with a poor RFS ( p  = 0.002), and OS ( p  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-34690-y